SDE2 and Miyoshi myopathy: Combined SDE2 silencing and pharmacological ATG5/7 activation (Antitumor agent-82) synergistically suppressed tumor growth in vitro and in vivo.<h4>Conclusion</h4>The SDE2-ATG5 axis serves as a critical regulator of the autophagy-ferroptosis crosstalk in MM.